Piramal Pharma Ltd (Mumbai)

Piramal Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 206.49, up 1.97% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.37% on the day, quoting at 24523.85. The Sensex is at 78409.43, down 0.02%. Piramal Pharma Ltd has gained around 16.08% in last one month. Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has gained around 2.37% in last one month and is currently quoting at 26597.5, down 0.44% on the day. The volume in the stock stood at 57.02 lakh shares today, compared to the daily average of 76.51 lakh shares in last one month.The PE of the stock is 34.78 based on TTM earnings ending June 26.

Net Loss of Piramal Pharma reported to Rs 69.39 crore in the quarter ended June 2026 as against net loss of Rs 81.70 crore during the previous quarter ended June 2025. Sales rose 17.39% to Rs 2269.92 crore in the quarter ended June 2026 as against Rs 1933.71 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales2269.921933.71 17 OPM %8.605.52 - PBDT216.0997.52 122 PBT-7.46-99.76 93 NP-69.39-81.70 15 Powered by Capital Market - Live

Piramal Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 195.03, up 0.83% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.98% on the day, quoting at 24220.8. The Sensex is at 77561.47, up 1.04%. Piramal Pharma Ltd has gained around 16.03% in last one month. Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has gained around 3.99% in last one month and is currently quoting at 25998.85, up 1.3% on the day. The volume in the stock stood at 88.78 lakh shares today, compared to the daily average of 76.36 lakh shares in last one month.The PE of the stock is 33.52 based on TTM earnings ending March 26.Powered by Capital Market - Live

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 29 July 2026.

Piramal Pharma announced that USFDA has issued an Establishment Inspection Report (EIR) for the company's manufacturing facility located at Sellersville (USA) and the inspection has now been successfully closed by USFDA.

Piramal Pharma announced that the Annual General Meeting(AGM) of the company will be held on 30 July 2026.

Piramal Pharma has allotted 21 lakh equity shares under ESOP on 05 June 2026. Consequently, the paid up equity share capital has increased to Rs. 1,331,34,81,300 (consisting of 133,13,48,130 equity shares of face value of Rs. 10/- each).

In a regulatory filing made on Sunday, the company stated that the US FDA had conducted a good manufacturing practices (GMP) inspection of Piramal Pharma's facility at Sellersville, USA, from 4th May 2026 to 8th May 2026. At the conclusion of the inspection, US FDA issued a Form-483, with three observations. At the closing meeting observations were recommended to be classified under VAI (voluntary action indicated) by inspectors. None of the observation relate to data integrity. The company is preparing a detailed response to the observations, which will be submitted to the US FDA within the stipulated timelines, Piramal Pharma said in a statement. Piramal Pharma offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. The company a consolidated net loss of Rs 8.83 crore in the quarter ended March 2026 as against net profit of Rs 153.50 crore during the previous quarter ended March 2025. Sales declined 0.08% to Rs 2,751.77 crore in Q4 FY26 as compared with Q4 FY25. The scrip shed 0.72% to currently trade at Rs 178.45 on the BSE. Powered by Capital Market - Live

Net loss of Piramal Pharma reported to Rs 8.83 crore in the quarter ended March 2026 as against net profit of Rs 153.50 crore during the previous quarter ended March 2025. Sales declined 0.08% to Rs 2751.77 crore in the quarter ended March 2026 as against Rs 2754.07 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 325.94 crore in the year ended March 2026 as against net profit of Rs 91.13 crore during the previous year ended March 2025. Sales declined 3.08% to Rs 8869.08 crore in the year ended March 2026 as against Rs 9151.18 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales2751.772754.07 0 8869.089151.18 -3 OPM %16.7420.37 -10.3915.79 - PBDT437.15515.56 -15 851.321230.98 -31 PBT218.77272.80 -20 20.08414.64 -95 NP-8.83153.50 PL -325.9491.13 PL Powered by Capital Market - Live

Piramal Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 168.78, up 2% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.74% on the day, quoting at 24075.7. The Sensex is at 77243.68, up 0.76%. Piramal Pharma Ltd has added around 23.61% in last one month. Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has added around 4.1% in last one month and is currently quoting at 22580.1, up 2.49% on the day. The volume in the stock stood at 68.33 lakh shares today, compared to the daily average of 61.68 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 169.6, up 2.1% on the day. Piramal Pharma Ltd is down 21.43% in last one year as compared to a 1.04% fall in NIFTY and a 5.64% fall in the Nifty Pharma index.The PE of the stock is 29.81 based on TTM earnings ending December 25.